D. Boral Capital Lowers Price Target for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock

D. Boral Capital has adjusted its expectations for Lineage Cell Therapeutics, reducing its target price for the stock from $3.00 to $2.00. This decision was communicated in a research report released to clients and investors on Tuesday. Despite the cut in the price target, D. Boral Capital has maintained a "buy" rating on the stock, suggesting that they believe there is still potential for significant upside. The new price target indicates a possible increase of approximately 204.88% compared to the stock's closing price prior to the announcement.

Other analysts have also reviewed Lineage Cell Therapeutics recently. In January, Maxim Group lowered its own price target from $5.00 to $3.00 while reiterating a "buy" rating. Furthermore, HC Wainwright confirmed a "buy" rating for the stock, setting an optimistic price target of $9.00 in a January report.

Current Trading Situation

As of Tuesday, Lineage Cell Therapeutics was trading at $0.66. The company has a market capitalization of approximately $144.60 million and a P/E ratio of -5.47, indicating that it is currently unprofitable. The stock has experienced a year of volatility, with a low of $0.48 and a high of $1.61 observed over the past twelve months.

Institutional Investment Trends

There has been notable activity from institutional investors regarding Lineage Cell Therapeutics. For example, SG Americas Securities LLC acquired a new stake valued around $46,000 in the third quarter. Similarly, Defender Capital LLC increased its holdings by 0.6%, bringing its total to 5,002,198 shares worth approximately $4.53 million after additional purchases. GSA Capital Partners LLP also made new investments in the company during the same quarter, valued at around $84,000. Additionally, MAI Capital Management raised its position, owning 1,674,679 shares valued at $1.516 million. Raffles Associates LP also increased its stake by 3.4%. Collectively, institutional investors now own around 62.47% of Lineage Cell Therapeutics' shares.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing innovative cell therapies to address unmet medical needs both in the United States and internationally. Their key products include OpRegen, which aims to treat dry age-related macular degeneration, OPC1 for cervical spinal cord injuries, and VAC, an immunotherapy targeting non-small cell lung cancer.

Stock, Price, Investment